Division of Cardiology, Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.
Division of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
Int J Cardiol. 2021 Sep 15;339:70-74. doi: 10.1016/j.ijcard.2021.07.008. Epub 2021 Jul 8.
Clinical implications of systemic atherosclerosis in patients with cardiogenic shock (CS) remain unclear. This study investigated the association between polyvascular disease (PVD) and clinical outcome in CS patients.
A total of 1247 CS patients was enrolled from the RESCUE registry, a multicenter, observational cohort between January 2014 and December 2018. They were divided into two groups according to presence of PVD, defined as ≥2 coexistence of coronary artery disease, peripheral arterial disease, or cerebrovascular disease. Primary outcome was all-cause death during 12 months of follow-up.
136 (10.9%) patients were diagnosed with PVD. The risk of 12-month all-cause death was significantly higher in the PVD group than in the non-PVD group (54.4% versus 40.4%, adjusted hazard ratio [HR] 1.31, 95% confidence interval [CI] 1.02-1.69, p = 0.034). There was a significant interaction between PVD and vasoactive inotropic score (VIS) (p for interaction = 0.014). Among the 945 patients with VIS <84, PVD was associated with a higher risk of 12-month all-cause death (unadjusted HR 1.77, 95% CI 1.30-2.41, p = 0.030); among the 302 patients with VIS ≥84, the incidence of 12-month all-cause death was similar between the PVD and non-PVD groups (unadjusted HR 1.03, 95% CI 0.68-1.56, p = 0.301).
Presence of PVD was associated with 12-month all-cause mortality in patients with CS, especially for less severe forms of CS patients with VIS <84. Clinicaltrials.govnumber:NCT02985008.
心源性休克(CS)患者全身性动脉粥样硬化的临床意义尚不清楚。本研究旨在探讨多血管疾病(PVD)与 CS 患者临床结局的关系。
本研究共纳入 1247 例来自 RESCUE 注册研究的 CS 患者,该研究为一项多中心、观察性队列研究,纳入时间为 2014 年 1 月至 2018 年 12 月。根据是否存在 PVD 将患者分为两组,PVD 定义为≥2 种并存的冠状动脉疾病、外周动脉疾病或脑血管疾病。主要终点为随访 12 个月时的全因死亡。
136 例(10.9%)患者被诊断为 PVD。与非 PVD 组相比,PVD 组 12 个月全因死亡风险显著升高(54.4% vs. 40.4%,调整后 HR 为 1.31,95%CI 为 1.02-1.69,p=0.034)。PVD 与血管活性正性肌力药物评分(VIS)之间存在显著交互作用(p 交互=0.014)。在 945 例 VIS<84 的患者中,PVD 与 12 个月全因死亡风险升高相关(未校正 HR 为 1.77,95%CI 为 1.30-2.41,p=0.030);在 302 例 VIS≥84 的患者中,PVD 组和非 PVD 组 12 个月全因死亡发生率相似(未校正 HR 为 1.03,95%CI 为 0.68-1.56,p=0.301)。
PVD 与 CS 患者 12 个月全因死亡率相关,尤其是对于 VIS<84 的 CS 患者,其严重程度较轻。
NCT02985008。